205 related articles for article (PubMed ID: 30917164)
41. A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Xu G; Wang B; Yang M; Qian W
Int J Clin Exp Pathol; 2015; 8(11):15025-9. PubMed ID: 26823839
[TBL] [Abstract][Full Text] [Related]
42. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulatory drugs in multiple myeloma.
Zangari M; Elice F; Tricot G
Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
[TBL] [Abstract][Full Text] [Related]
44. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
46. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
47. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
An R; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
[TBL] [Abstract][Full Text] [Related]
48. [Triplets therapy for the patients of multiple myeloma].
Ishida T
Nihon Rinsho; 2013 Sep; 71(9):1691-6. PubMed ID: 24205736
[TBL] [Abstract][Full Text] [Related]
49. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
50. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
51. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
[TBL] [Abstract][Full Text] [Related]
52. The role of immunomodulatory drugs in multiple myeloma.
Anderson KC
Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
[TBL] [Abstract][Full Text] [Related]
53. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
54. [Multiple myeloma and other plasma cell dyscrasias].
Nagy Z
Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
[TBL] [Abstract][Full Text] [Related]
55. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
56. Immunomodulation of multiple myeloma.
Tohnya TM; Figg WD
Cancer Biol Ther; 2004 Nov; 3(11):1060-1. PubMed ID: 15640623
[TBL] [Abstract][Full Text] [Related]
57. A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.
Kowalski TW; Feira MF; Lord VO; Gomes JDA; Giudicelli GC; Fraga LR; Sanseverino MTV; Recamonde-Mendoza M; Schuler-Faccini L; Vianna FSL
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511270
[TBL] [Abstract][Full Text] [Related]
58. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.
Leclerc V; Karlin L; Herledan C; Marchal L; Baudouin A; Gouraud A; Caffin AG; Larbre V; Lazareth A; Bachy E; Salles G; Ghesquières H; Rioufol C; Ranchon F
J Cancer Res Clin Oncol; 2022 Apr; 148(4):975-984. PubMed ID: 34143239
[TBL] [Abstract][Full Text] [Related]
59. Pomalidomide for the management of refractory multiple myeloma.
Summers BB; Cole SW; Olin JL
Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
[TBL] [Abstract][Full Text] [Related]
60. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
